Background {#Sec1}
==========

Doxycycline is an effective anti-malarial prophylactic drug when administered as a monotherapy 1 day before, daily during, and for 4 weeks after return from travel to an area where malaria is endemic. Doxycycline is currently a recommended chemoprophylactic regimen for travellers visiting areas where malaria is endemic and has a high prevalence of chloroquine or multidrug resistance \[[@CR1]--[@CR3]\]. The World Health Organization also recommends doxycycline in combination with quinine or artesunate as the second-line treatment for uncomplicated *Plasmodium falciparum* malaria \[[@CR2]\].

Most prophylactic failures of doxycycline against *P. falciparum* were associated with the use of inadequate, low doses or poor compliance \[[@CR4]--[@CR6]\]. However, resistance could also explain prophylactic failures with doxycycline. Cyclines resistance has been documented in *Plasmodium berghei* as a consequence of minocycline drug pressure in a *P.berghei* murine malaria model \[[@CR7]\]. Recently, one prophylactic failure has been reported \[[@CR8]\].

A Bayesian mixture modelling approach identified three different phenotypes (low, medium, and high doxycycline IC~50~ phenotypic groups) among *P. falciparum* African clinical isolates \[[@CR9], [@CR10]\]. Using 90 isolates from 14 African countries, it was demonstrated that increases in copy numbers of *P. falciparum* metabolite drug transporter gene (*Pfmdt*, PFE0825w) and *P. falciparum* GTPase TetQ gene (*PfTetQ*, PFL1710c) are associated with reduced susceptibility to doxycycline \[[@CR11]\], and this association was later confirmed in African *P. falciparum* isolates \[[@CR9]\]. In addition, isolates with PfTetQ KYNNNN motif repeats \<3 are associated with in vitro reduced susceptibility to doxycycline and with a significantly higher probability of having an IC~50~ above the doxycycline resistance threshold of 35 µM (odds ratio of 15) \[[@CR11], [@CR12]\]. The isolate obtained from the patient with prophylactic resistance to doxycycline harboured two copies of *pfmdt* and two PfTetQ KYNNNN motif repeats \[[@CR8]\], consistent with previous in vitro data \[[@CR12]\].

However, some recent publications have demonstrated that these molecular markers were certainly not only encountered in cases of reduced susceptibility to doxycycline \[[@CR13], [@CR14]\] and were not associated with resistance in Thai isolates \[[@CR14]\]. Therefore, it is necessary to investigate other hypotheses. Based on bacterial world, proteins homologue to those implicated in doxycycline resistance in bacteria were identified in silico in *P. falciparum*.

Indeed, cyclines bind to proteins S4, S7, S9, and S17 of the 30S small ribosomal sub-unit and various ribonucleic acids of the 16S ribosomal RNA, preventing the binding of aminoacyl-transfer RNA to site A of the ribosome and thus blocking the elongation step of translation in bacteria \[[@CR15]\]. Specific mutations in genes coding these targets can confer resistance to tetracyclines in bacteria. However, no point mutation was found in small sub-unit plastid ribosomal homologue plasmodial genes in African isolates (*pfrps7*, *pfrps9*, and *pfrps17*, although S7, S9, and S17) \[[@CR11]\]. It has been also shown that resistance to tetracycline was mediated by mutations in the 16S rRNA gene, particularly in *Helicobacter pylori* or in *Propionibacterium acnes* \[[@CR16]--[@CR18]\]. An analogue of this gene exists in *P. falciparum* apicoplast, the small sub-unit ribosomal RNA gene, the *pfssrRNA* gene, (PFC10_API0057) \[[@CR19]--[@CR22]\]. First, the *pfssrRNA* gene shares 58 and 62 % identities with the 16S rRNA gene of *Propionibacterium acnes* and *Helicobacter pylori*, respectively. Secondly, this gene belongs to the apicoplast, an organelle related to the chloroplast of plant cells that contains its own genome-encoding, prokaryote-like, ribosomal RNAs, tRNAs and some proteins \[[@CR23]\]. Three studies confirmed the specific action of cyclines on the apicoplast of *P. falciparum* \[[@CR24]--[@CR26]\]. A parasite exposed to 1 µM of doxycycline for 20 h presented during the next cycle (72 h), the inhibition of apicoplastic replication visualized by confocal fluorescence microscopy, electron microscopy and an analysis of the parasite transcriptome \[[@CR24]\]. The most recently published study confirms the action of doxycycline on the apicoplast but in two stages, with an immediate toxic effect and a toxic effect measurable after cell division \[[@CR25]\]. A proteomic approach confirmed the specific deregulation of proteins involved in apicoplast metabolism after doxycycline treatment \[[@CR27]\].

Thus, the aim of this study was to identify specific point mutations in this plasmodial ribosomal gene, according to what is observed in other species, to determine whether this gene could be involved in reduced susceptibility to doxycycline. For this purpose, the apicoplastic *pfssrRNA* gene from the 89 African and 89 Thai *P. falciparum* isolates, belonging to phenotypic groups differing in doxycycline IC~50~ values and already analysed for *pftetQ* and *pfmdt* genes, was sequenced and analysed \[[@CR9], [@CR14]\].

Methods {#Sec2}
=======

*Plasmodium falciparum* isolates {#Sec3}
--------------------------------

A total of 89 African *P. falciparum* isolates, obtained at the French National Reference Centre for Imported Malaria, Hôpital Bichat, Paris, from patients hospitalized with malaria after having returned to France between January 2006 and December 2010, and 89 isolates obtained from the Shoklo Malaria Research Unit (Mae Sot, Thailand) from patients infected with *P. falciparum* from 2001 to 2010, were used. These isolates were previously tested to evaluate their *pfmdt* and *pftetQ* genes copy numbers \[[@CR9], [@CR14]\].

Consent {#Sec4}
-------

Informed consent was not required as the sampling procedures and testing are part of the French national recommendations for the care and surveillance of malaria.

Concerning the Thai isolates, written informed consent translated into the patient's own language was obtained from each participant, whose signature was witnessed. The studies were approved by the Ethics Committees of the Faculty of Tropical Medicine, Mahidol University and Oxford University.

Amplification and sequencing of *pfssrRNA* gene {#Sec5}
-----------------------------------------------

*PfssrRNA* (PFC10_API0057) was amplified by polymerase chain reaction (PCR) using the following primers: 5′-AGCTAATGGTGAGATTTGAACTCA-3′ (forward) and 5′-CGTCGTGAGACAGTTCGGTC-3′ (reverse) (Eurogentec, Angers, France), designed with the NCBI/Primer-BLAST online tool.

The reaction mixture included 2 µl of genomic DNA, 2.5 µl of 10× reaction buffer (Eurogentec), 0.5 µM of each primer, 200 µM of deoxynucleoside triphosphate mixture (dGTP, dATP, dTTP and dCTP) (Euromedex, Souffelweyersheim, France), and 1.5 mM of MgCl~2~ and 1.25 units of RedGoldStar^®^ DNA polymerase (Eurogentec) in a final volume of 25 µL. The thermal cycler (T3 Biometra, Archamps, France) was programmed as follows: an initial 94 °C for 2 min followed by 40 cycles of 94 °C for 30 s, 55 °C for 30 s and 60 °C for 2 min, and a final extension step of 60 °C for 5 min. The PCR products were loaded on 1 % agarose gel containing 0.5 μg/mL ethidium bromide. Amplicons were purified using the QIAquick 96 PCR BioRobot Kit and an automated protocol on the BioRobot 8000 workstation (Qiagen, Courtaboeuf, France). The purified fragments were sequenced using BigDye Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems) using the following primers: 5′-ACTAGTGTATTTCGGTTAACAGCCG-3′ (forward), 5′-ACCCTTATCAAGAGTATGTTTTAACCAT-3′ (reverse) and Pf_SSU_rRNA_R1481 CTTAAGAACTTATTCACCGCTA (reverse). The sequence reaction products were purified using the BigDye XTerminator^®^ Purification Kit (Applied Biosystems), in accordance with the manufacturer's instructions. The purified products were sequenced using an ABI Prism 3100 analyser (Applied Biosystems), and the sequences were analysed using Vector NTI advance (TM) software (version 11, Invitrogen, Cergy Pontoise, France).

Results {#Sec6}
=======

In *Helicobacter pylori*, tetracycline resistance has not been associated with efflux or ribosomal protection proteins but rather attributed to mutations in the 16S rRNA-encoding genes that affect the binding site of tetracycline \[[@CR16]--[@CR18]\]. Tetracycline resistance mediated by mutations in the 16S rRNA was first found in *Propionibacterium acnes*, and a mutation from G to C was reported at position 1058 (*Escherichia coli* numbering) in their 16S rRNA genes \[[@CR17]\]. A triplet mutation in the same 16S rRNA domain (965--967; *E. coli* numbering) was also found \[[@CR24], [@CR28]--[@CR30]\] and is located in the primary tetracycline-binding site \[[@CR1], [@CR15]\]. However, the sequencing of *pfssrRNA* did not reveal a polymorphism in *P. falciparum*. There was no single nucleotide polymorphism in the *pfssrRNA* gene in either the 89 African isolates, regardless of the phenotypic group for doxycycline (group A of low doxycycline IC~50~ \[mean IC~50~ = 3.88 µM; confident interval 95 % (CI 95 %) \[3.39--4.37\], no = 30\], group B of moderate IC~50~ \[mean IC~50~ = 16.97 µM; CI 95 % \[16.45--17.49\]; no = 30\]) and group C of high IC~50~ \[mean IC~50~ = 34.60 µM, CI 95 % \[31.3--37.9\], no = 29), or the 89 Thai isolates (group A \[mean IC~50~ = 3.64 µM, CI 95 % \[3.29--3.99\], no = 30\], group B \[mean IC~50~ = 14.73 µM, CI 95 % \[14.6--14.85\], no = 30\] and group C \[mean IC50 = 28.94 µM, CI 95 % \[26.51--31.37\], no = 29\]). No sequence polymorphism in the *pfssrRNA* gene was observed by comparison with the reference strain 3D7. This gene was not associated with reduced susceptibility to doxycycline in either African or Thai *P. falciparum* isolates and the small sub-unit ribosomal RNA seemed to be not a target for doxycycline.

Conclusions {#Sec7}
===========

The decreased susceptibility of *P. falciparum* to doxycycline is certainly multigenic. *Pfmdt* and *pftetQ* genes polymorphism and number of copies are involved partly to the decreased susceptibility. Intensive research into identifying in vitro markers associated with decreased susceptibility should allow survey of the emergence of doxycycline resistance. Another hypothesis to be explored is some apicoplastic genes, which could be involved in artemisinin resistance \[[@CR31]\], such as *arps10*, encoding the apicoplast ribosomal protein S10 precursor, and *fd*, encoding the ferredoxin protein, a key component of the apicoplast electron transport chain.
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